Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4221919 | 0.83 | P2RY12 (0.51) | ALDH1A1KMT2ALMNAP2RY12MAPK1 | |
| SCHEMBL13428810 | 0.82 | ALDH1A1 (0.46) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL13428482 | 0.80 | LMNA (0.45) | ALDH1A1KMT2ASMN1; SMN2TDP1LMNA | |
| SCHEMBL13428467 | 0.78 | POLB (0.44) | ALDH1A1KMT2ASMN1; SMN2TDP1LMNA | |
| SCHEMBL13428568 | 0.74 | HPGD (0.40) | ALDH1A1KMT2ASMN1; SMN2TDP1LMNA | |
| SCHEMBL1179270 | 0.74 | L3MBTL1 (0.46) | L3MBTL1KMT2ASMN1; SMN2P2RY12PKM | |
| SCHEMBL4227879 | 0.74 | P2RY12 (0.47) | P2RY12MAPT | |
| SCHEMBL4232969 | 0.74 | P2RY12 (0.47) | P2RY12MAPT | |
| SCHEMBL5122057 | 0.73 | ALOX15 (0.64) | L3MBTL1ALDH1A1KMT2ASMN1; SMN2LMNA | |
| SCHEMBL13428802 | 0.73 | P2RY12 (0.59) | L3MBTL1ALDH1A1LMNAP2RY12MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | ASTELLAS PHARMA INC. (JP) | 2010-03-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100069388-A1 | N-HYDROXYACRYLAMIDE COMPOUNDS | HDAC1, HDAC11, HDAC2 | L3MBTL1 1127/4885ALDH1A1 1516/4885KMT2A 31/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.